查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1365783

糖尿病腎臟病市場：依藥物類別、類型、配銷通路：2022-2031年全球機會分析與產業預測

Diabetic nephropathy Market By Drugs Class, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2022-2031
出版日期: | 出版商: Allied Market Research | 英文 266 Pages | 商品交期: 2-3個工作天內

價格

2021年糖尿病腎臟病變市場價值為19億美元，預計2022年至2031年年複合成長率為6%，到2031年將達33億美元。

糖尿病腎臟病是一種體內糖值長期居高不下的代謝性疾病。糖尿病有兩種類型：1 型和 2 型。糖尿病腎臟病是一種糖尿病影響腎臟的疾病，導致慢性腎臟病和腎臟損傷。糖尿病腎臟病是糖尿病患者死亡率和發病率最重要的併發症之一。腎臟病影響腎臟排放體內廢棄物和多餘水分的能力。預防或延緩糖尿病腎臟病變的最佳方法是保持健康的生活方式並妥善管理糖尿病和高血壓。腎臟疾病可進展為腎衰竭，也稱為末期腎功能衰竭。腎衰竭是一種危及生命的疾病。在此階段，治療選擇包括透析或腎臟移植。

糖尿病腎病變市場-IMG1

糖尿病腎臟病通常是在常規檢查中診斷出來的，這是糖尿病管理的一部分。用於診斷糖尿病腎臟病變的常規檢查包括尿液白蛋白檢查、白蛋白/肌酸酐比值、腎小球濾過率（GFR），以及影像檢查（電腦斷層掃描、MRI）和切片檢查等專門檢查。

糖尿病腎臟病變的治療對於患者來說是非常必要的。治療糖尿病腎臟病的第一步是治療和控制糖尿病和高血壓。這包括用餐、生活方式的改變、運動、處方藥、血壓控制藥物、血糖控制藥物、G蛋白偶聯受體（GPCR）藥物和抗氧化發炎調節藥物。此外，對於晚期糖尿病腎病變也進行腎臟透析、移植和症狀治療。糖尿病腎臟病市場快速成長。推動糖尿病腎臟病變市場成長的主要因素包括患有糖尿病的老年人口的增加、糖尿病人口的增加以及各種腎臟疾病發病率的上升。例如，根據《營養與代謝雜誌》報告，埃塞俄比亞西北部貢德爾大學總醫院的一項研究發現，糖尿病腎臟病變的盛行率為每10,000名患者中有14例（95%置信區間為10.8至17.7） 。此外，63 名 (13.6%) 糖尿病 (DM) 患者出現糖尿病腎臟病。患有心臟疾病和貧血的第二型糖尿病患者患糖尿病腎臟病的風險增加。因此，這些因素推動市場成長。

例如，根據國家糖尿病統計最新報告，2017年至2020年，美國有3730萬人患有糖尿病（占美國人口的11.3%），其中確診人數為2870萬人，其中成年人為2850萬人，糖尿病患者為850 萬人。（23.0%的成人） 未確診。

此外，糖尿病和慢性腎臟病的迅速增加導致糖尿病腎臟病變的腎臟病，進一步需要抗糖尿病腎臟病藥物。血管張力素轉化酵素抑制劑是治療糖尿病腎臟病的熱門藥物。 2型糖尿病是最受歡迎的糖尿病腎臟病，吸引了客戶的關注，並推動糖尿病腎臟病變市場的成長。此外，技術進步、各種產品發布以及主要企業之間的策略（例如收購、聯盟和協議）推動糖尿病腎臟病市場。例如，阿斯特捷利康公司 (AstraZeneca Plc.) 的 Forxiga 在日本和歐洲獲得核准，作為維持強勁競爭和改善產品系列的關鍵發展策略。

然而，由於不利的償付和併發症發生率，更嚴格的法規標準和更長的藥物核准期限制了市場成長。糖尿病腎臟病變缺乏綜合治療方法也限制了糖尿病腎臟病變市場的成長。

此外，由於糖尿病和肥胖症盛行率上升、藥物研發和藥物開發的研發投資增加以及人們對糖尿病和腎臟相關疾病的認知不斷提高，預計醫療業務將出現成長。因此，預計主要企業在預測期內將獲得投資該市場的豐厚機會。

糖尿病腎臟病變市場按藥物類別、類型、配銷通路和地區進行細分。依藥物類別分為血管收縮素轉化酵素抑制劑、血管收縮素受體拮抗、鈣通道拮抗、利尿劑、腎素抑制劑等。依類型分類，市場分為第1 型糖尿病和第2 型糖尿病。按配銷通路分為醫院藥房、線上供應商、藥局和零售藥房。依地區分類，市場分為北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、歐洲其他地區）、亞太地區（日本、中國、澳洲、印度、韓國、其他地區） ） 、LAMEA（巴西、南非、沙烏地阿拉伯和LAMEA其他地區）。

本報告介紹的主要企業包括Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi。

目錄

第1章 簡介

第2章 執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 糖尿病老年人口快速增加，慢性腎臟病、肥胖及高血壓盛行率上升
      • 提高對糖尿病腎臟病的認知和診斷測試
    • 抑制因素
      • 法規規則嚴格，藥品核准時間長
    • 機會
      • 糖尿病腎臟病聯合治療的增加
      • 增加藥物研發與開發的研發投入
  • COVID-19 市場影響分析

第4章 糖尿病腎臟病變市場：依藥物類別

  • 概述
  • 血管收縮素轉化酵素抑制劑
  • 血管收縮素受體阻斷劑
  • 鈣拮抗
  • 利尿劑
  • 腎素抑制劑
  • 其他

第5章 糖尿病腎臟病變市場：依類型

  • 概述
  • 1型糖尿病
  • 2型糖尿病

第6章 糖尿病腎臟病市場：依配銷通路

  • 概述
  • 醫院藥房
  • 線上提供者
  • 藥局和零售藥房

第7章 糖尿病腎臟病變市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲、中東、非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2021年主要企業定位

第9章 公司簡介

  • AbbVie Inc.
  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co
  • Astrazenica Plc
  • Novartis AG
  • Pfizer Inc.
  • Reata Pharmaceuticals
  • Sanofi
Product Code: A16604

According to a new report published by Allied Market Research, titled, "Diabetic nephropathy Market," The diabetic nephropathy market was valued at $1.9 billion in 2021, and is estimated to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.The diabetic nephropathy market is expected to reach $3,338.50 million by 2031. Diabetic nephropathy is the metabolic disorder in which the body has high sugar levels for prolonged period. Diabetes is of two types i.e., type-1 and type-2. Diabetic nephropathy is a medical condition in which diabetes affect kidney and causes chronic kidney diseases and kidney disorders. Diabetic nephropathy is one of the most significant complications, in terms of mortality and morbidity for patients with diabetes. It affects the ability of kidneys to do their usual work of removing waste products and extra fluid from body. The best way to prevent or delay diabetic nephropathy is by maintaining a healthy lifestyle and adequately managing your diabetes and high blood pressure. Kidney disease may progress to kidney failure, also called end-stage kidney disease. Kidney failure is a life-threatening condition. At this stage, treatment options are dialysis or a kidney transplant.

Diabetic nephropathy Market - IMG1

Diabetic nephropathy is usually diagnosed during routine testing, which is a part of the diabetes management. Routine test used for diagnosis of diabetic nephropathy include urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR) and other special tests such as imaging tests (CT scanning, MRI) and Kidney biopsy.

Treatments of diabetic nephropathy are very necessary for patients. The first step in treating diabetic nephropathy is to treat and control diabetes and high blood pressure (hypertension). This includes diet, lifestyle changes, exercise, prescription medications, blood pressure control medicine, blood sugar control medicine, G-Protein Coupled Receptors (GPCR), and antioxidant inflammation modulators medicine. Furthermore, kidney dialysis, transplant, and symptom management treatment are also used for advanced diabetic kidney diseases. The diabetic nephropathy market is growing at rapid rate. Major factors driving growth of the diabetic nephropathy market include increase in geriatric population suffering from diabetes, increase in diabetic population, and rise in incidences of various kidney diseases. For instance, according to the Journal of Nutrition and Metabolism, in a survey at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, the incidence rate of diabetic nephropathy was 14 (95% CI 10.8-17.7) cases per 10,000 patients. In addition, 63 (13.6%) diabetes mellitus (DM) patients developed diabetic nephropathy. Type 2 DM patients who had coronary heart diseases and anemia were at higher hazard of developing diabetic nephropathy. Hence, such factors propel the market growth.

For instance, according to the National Diabetes Statistics Latest Report, 37.3 million people had diabetes (11.3% of the US population) in which 28.7 million people, including 28.5 million adults were diagnosed and 8.5 million people (23.0% of adults are undiagnosed) were undiagnosed in the U.S from 2017 to 2020.

Moreover, surge in diabetes and chronic kidney diseases leads to increase in number of diabetic nephropathies, which further require anti-diabetic nephropathy medicines, thus propelling adoption of anti-diabetic nephropathy medicine. Angiotensin-converting enzyme inhibitors have become more popular among products of diabetic nephropathy. Type-2 diabetes is the most trending diabetic nephropathy that draws attention of customers, fueling growth of the diabetic nephropathy market. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, AstraZeneca Plc. got approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.

However, unfavorable reimbursements as well as complications such as the market growth is limited by stricter regulatory standards and lengthy drug approval times. The market growth of the diabetic nephropathy is also restrained, owing to lack of comprehensive therapeutic therapy for diabetic nephropathy.

Furthermore, healthcare business is predicted to witness growth, owing to rise in prevalence of diabetes and obesity, increase in R&D investments in drug discovery & development, and rise in awareness regarding diabetes and kidney-related disorders. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The diabetic nephropathy market is segmented on the basis of drug class, type, distribution channel, and region. On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor, and others. By type, the market is segregated into type-1 diabetes and type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug stores & retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)

Major players profiled in the report are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Product Benchmarking / Product specification and applications
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • SWOT Analysis

Key Market Segments

By Distribution Channel

  • Hospital Pharmacy
  • Online Providers
  • Drug Stores and Retail Pharmacy

By Drugs Class

  • Angiotensin-converting Enzyme Inhibitors
  • Angiotensin Receptor Blockers
  • Calcium Channel Blocker
  • Diuretics
  • Renin Inhibitor
  • Others

By Type

  • Type-1 Diabetes
  • Type-2 Diabetes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bayer AG
    • Abbott Laboratories
    • Astrazenica Plc
    • Eli Lilly and Company
    • Pfizer Inc.
    • Sanofi
    • Novartis AG
    • Merck & Co
    • AbbVie Inc.
    • Reata Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in number of geriatric populations suffering from diabetes and rise in prevalence of chronic kidney diseases, obesity, and hypertension
      • 3.4.1.2. Rise in awareness regarding diabetic nephropathy and increase in diagnostic tests
    • 3.4.2. Restraints
      • 3.4.2.1. Strict regulatory rules and lengthy drug approval times
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in use of combination therapy for diabetic nephropathy
      • 3.4.3.2. Increase in R&D investments in drug discovery and development
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Angiotensin-converting Enzyme Inhibitors
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Angiotensin Receptor Blockers
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Calcium Channel Blocker
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Diuretics
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Renin Inhibitor
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. Others
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country

CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Type-1 Diabetes
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Type-2 Diabetes
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacy
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacy
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drugs Class
    • 7.2.3. Market size and forecast, by Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drugs Class
      • 7.2.5.1.3. Market size and forecast, by Type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drugs Class
      • 7.2.5.2.3. Market size and forecast, by Type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drugs Class
      • 7.2.5.3.3. Market size and forecast, by Type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drugs Class
    • 7.3.3. Market size and forecast, by Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drugs Class
      • 7.3.5.1.3. Market size and forecast, by Type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drugs Class
      • 7.3.5.2.3. Market size and forecast, by Type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. U.K.
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drugs Class
      • 7.3.5.3.3. Market size and forecast, by Type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drugs Class
      • 7.3.5.4.3. Market size and forecast, by Type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drugs Class
      • 7.3.5.5.3. Market size and forecast, by Type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drugs Class
      • 7.3.5.6.3. Market size and forecast, by Type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drugs Class
    • 7.4.3. Market size and forecast, by Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drugs Class
      • 7.4.5.1.3. Market size and forecast, by Type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drugs Class
      • 7.4.5.2.3. Market size and forecast, by Type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drugs Class
      • 7.4.5.3.3. Market size and forecast, by Type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drugs Class
      • 7.4.5.4.3. Market size and forecast, by Type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drugs Class
      • 7.4.5.5.3. Market size and forecast, by Type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drugs Class
      • 7.4.5.6.3. Market size and forecast, by Type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drugs Class
    • 7.5.3. Market size and forecast, by Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drugs Class
      • 7.5.5.1.3. Market size and forecast, by Type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drugs Class
      • 7.5.5.2.3. Market size and forecast, by Type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drugs Class
      • 7.5.5.3.3. Market size and forecast, by Type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drugs Class
      • 7.5.5.4.3. Market size and forecast, by Type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Abbott Laboratories
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Bayer AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Eli Lilly and Company
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Merck & Co
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Astrazenica Plc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Novartis AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Pfizer Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Reata Pharmaceuticals
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Sanofi
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 02. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. GLOBAL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 09. DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 12. DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. DIABETIC NEPHROPATHY MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. U.S. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 21. U.S. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 22. U.S. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 23. CANADA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 24. CANADA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 25. CANADA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 27. MEXICO DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 28. MEXICO DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 32. EUROPE DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 34. GERMANY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. GERMANY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 37. FRANCE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. FRANCE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 39. U.K. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 40. U.K. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. U.K. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 42. ITALY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 43. ITALY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. ITALY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 47. SPAIN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 50. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. JAPAN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. CHINA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 68. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 69. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 75. LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 76. LAMEA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 78. BRAZIL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 79. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 81. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 82. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 85. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 87. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 88. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 89. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 90. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 91. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 92. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 93. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 94. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 95. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 96. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 97. BAYER AG: KEY EXECUTIVES
  • TABLE 98. BAYER AG: COMPANY SNAPSHOT
  • TABLE 99. BAYER AG: PRODUCT SEGMENTS
  • TABLE 100. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 105. MERCK & CO: KEY EXECUTIVES
  • TABLE 106. MERCK & CO: COMPANY SNAPSHOT
  • TABLE 107. MERCK & CO: PRODUCT SEGMENTS
  • TABLE 108. MERCK & CO: PRODUCT PORTFOLIO
  • TABLE 109. ASTRAZENICA PLC: KEY EXECUTIVES
  • TABLE 110. ASTRAZENICA PLC: COMPANY SNAPSHOT
  • TABLE 111. ASTRAZENICA PLC: PRODUCT SEGMENTS
  • TABLE 112. ASTRAZENICA PLC: PRODUCT PORTFOLIO
  • TABLE 113. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 117. PFIZER INC.: KEY EXECUTIVES
  • TABLE 118. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 119. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 120. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 121. REATA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 122. REATA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 123. REATA PHARMACEUTICALS: SERVICE SEGMENTS
  • TABLE 124. REATA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 125. SANOFI: KEY EXECUTIVES
  • TABLE 126. SANOFI: COMPANY SNAPSHOT
  • TABLE 127. SANOFI: PRODUCT SEGMENTS
  • TABLE 128. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. DIABETIC NEPHROPATHY MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF DIABETIC NEPHROPATHY MARKET,2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN DIABETIC NEPHROPATHY MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL DIABETIC NEPHROPATHY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 17. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 24. DIABETIC NEPHROPATHY MARKET BY REGION, 2021(%)
  • FIGURE 25. U.S. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. CANADA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. MEXICO DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. GERMANY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. FRANCE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. U.K. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. ITALY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. SPAIN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. JAPAN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. CHINA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. INDIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. BRAZIL DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48. COMPETITIVE DASHBOARD
  • FIGURE 49. COMPETITIVE HEATMAP: DIABETIC NEPHROPATHY MARKET
  • FIGURE 50. TOP PLAYER POSITIONING, 2021
  • FIGURE 51. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. REATA PHARMACEUTICALS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 67. REATA PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)